Alternate TKI formulations, like nilotinib, are engineered to be superior to parent compounds. They remove dietary restrictions (fasting) and interference from acid reducers, ensuring consistent drug exposure. This can reduce adverse effects and improve patient quality of life, moving beyond the simple 'biosimilar' label.
Common, OTC acid-reducing drugs can drastically inhibit TKI absorption, sometimes by more than half. This frequently overlooked drug interaction can cause suboptimal responses and treatment failure in CML patients. The lack of patient questioning about OTC use presents a significant and avoidable clinical risk.
Newer TKI formulations ensure consistent drug absorption, correcting for under-dosing caused by food or other medications. While improving efficacy, this means more patients may experience the drug's known side effects. What seems like new toxicity could be the drug’s true profile, no longer masked by poor absorption.